HC Wainwright & Co. maintains Tarsus Pharmaceuticals at Buy, raises price target to $106 from $88

What happened

HC Wainwright & Co. kept its Buy rating on Tarsus Pharmaceuticals and raised its price target to $106 from $88, a 20.5% increase. The new target was described as 45.9% above Tarsus’s Nov. 3 closing share price of $72.64.

Confirmed

Global impact / market context

The higher target signals that HC Wainwright sees more potential share-price appreciation than before, while keeping its positive rating. If investors act on that view, buying could support the share price, but the target is an analyst estimate, not a guaranteed outcome or company financial result.

Analyst inference

This update concerns an analyst’s view of Tarsus Pharmaceuticals rather than a reported change in the company’s operations, sales, or cash available. The target compares an estimate with a past closing price; it does not establish what the shares will be worth later.

Analyst inference

What to watch

1. Whether Tarsus’s share price moves toward or away from the $106 target; the article gives no subsequent price or market reaction. Analyst inference
2. Any later changes to HC Wainwright’s Buy rating or price target, which would show whether its published view has shifted. Analyst inference
3. Future company results or disclosures that could provide evidence for or against the analyst’s higher target; none are described in this update. Analyst inference

Evidence

• Original source link unavailable